Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Back to Childhood Acute Myeloid Leukemia

Childhood Acute Myeloid Leukemia — NIH Grants & Funding

Active and recent NIH-funded research on Childhood Acute Myeloid Leukemia. Data from NIH RePORTER, last 36 months.

MONDO:0004996

NIH-funded research on Childhood Acute Myeloid Leukemia

active grants

institutions

researchers

new in last 12 mo.

$24.8M in NIH funding over the last 36 months. Data from NIH RePORTER.

I'm looking for:

Or filter by research focus

Only show active grants

Basic Science(14)

Basic ScienceZIACompleted

Detection, prevention and treatment of acute myeloid leukemia (AML) relapse.

Hourigan, Christopher·NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

$2,779,530 (FY2023)

Childhood Acute Myeloid Leukemia — NIH Grants & Funding

Basic Science(14)

Detection, prevention and treatment of acute myeloid leukemia (AML) relapse.

Cross-species development and credentialing of pediatric AML models

An Accurate Machine Learning Framework for Childhood Acute Myeloid Leukemia Subtype Identification by Integrating Bulk and Single-Cell Multi-Omics Data Within and Beyond the CCDI Ecosystem

Overcoming Therapy Resistance in Fusion Oncoprotein Driven Pediatric Leukemia

The paradox of myeloid leukemia of Down syndrome

Characterizing and Targeting the NUP98 Fusion Oncoprotein Interactome

Activation of Proto-Oncogenes by Chromosomal Translocation

Towards a structural understanding of transcriptional regulation by ZMYM2-KDM1A-CoREST

Metabolic regulation of oxidative phosphorylation in pediatric AML relapse

Post-Transcriptional Regulation is a Therapeutic Vulnerability of Acute Myeloid Leukemia

Translational(2)

Exploiting the Metabolic Dependencies of Pediatric AML

Preclinical Validation of Personalized Molecular Assays for Measurable Residual Disease Monitoring in Pediatric AML

Clinical(4)

Predicting and Monitoring for Cardiac Toxicity in Pediatric AML

Integrated Systems Biology of Pediatric AML

Treatment-Related Cardiotoxicity in Children with Relapsed Acute Myeloid Leukemia - Natural History, Occurrence and Implications

Co-targeting BET Bromodomain Proteins and Aberrant Signaling in AML.

Epi / Nat. History(2)

Evaluating inherited genetic variation and outcome among children andadolescents treated for acute myeloid leukemia

Genomics of AML Prognosis

Gene/Cell Therapy(3)

Engineering best in class Acute Myeloid Leukemia (AML) CAR-T therapies by enhancing persistence and defining the immune landscape of AML

CONCEPT SBIR - T-CELL RECEPTORS FOR TREATING PEDIATRIC ACUTE MYELOID LEUKEMIA

Novel non-genotoxic ligand-based CD117-directed CAR T conditioning in the context of hematopoietic stem cell transplantation and leukemia treatment

Biomarker / Dx(3)

UBTF Tandem Duplications in Pediatric Acute Myeloid Leukemia

Defining the novel cancer testis antigen HSPA1L as immunotherapeutic target in AML

Early Treatment-Related Cardiotoxicity and Subsequent Outcomes in Pediatric Acute Myeloid Leukemia: an Assessment of Development, Progression and Mitigation